Is Spravato (esketamine) contraindicated for bipolar II depression?

Spravato is NOT contraindicated for bipolar II depression

Spravato (esketamine) does not have an absolute contraindication for bipolar II depression, though it was not studied in bipolar disorder during FDA approval trials and requires concurrent mood stabilizer therapy. 1

FDA-Approved Contraindications

The FDA label for Spravato lists only three absolute contraindications 1:

• Aneurysmal vascular disease or arteriovenous malformation
• History of intracerebral hemorrhage
• Hypersensitivity to esketamine or ketamine

Bipolar disorder is notably absent from this contraindication list.

Critical Clinical Context

While not contraindicated, the manufacturer explicitly states that esketamine "has not been studied, and is not indicated, for patients with bipolar disorder" 2. This creates a nuanced clinical situation where the drug is not prohibited but lacks formal approval for this indication.

Evidence for Use in Bipolar Depression

Efficacy Data

Recent real-world evidence strongly supports esketamine's use in bipolar depression when combined with mood stabilizers:

• A 2025 retrospective cohort of 2,126 patients found esketamine plus mood stabilizers significantly reduced suicide-related outcomes across all time intervals (1-7 days through 1 year) without increasing manic switch risk 3

• A 2023 naturalistic multicenter study comparing 35 bipolar TRD patients to 35 unipolar TRD patients showed equivalent response and remission rates with no treatment-emergent affective switches 4

• A 2024 Yale cohort study of 45 bipolar depression patients treated with ketamine/esketamine found 39% response rate and 13.2% remission rate during acute treatment, with zero manic/hypomanic episodes during the acute twice-weekly phase 5

Safety Profile Regarding Manic Switch

The risk of manic switch appears minimal during acute treatment but requires monitoring during maintenance:

• During acute treatment (twice weekly for 4 weeks): No manic switches observed across multiple studies 4, 5

• During maintenance treatment: The Yale study found 28.9% of patients experienced hypomania/mania during extended maintenance (1 event per 2.7 patient-years), with only 1 severe event requiring hospitalization 5

• The 2025 TriNetX study showed significantly LOWER manic switch risk at 1-180 days (HR=0.643) and 1-365 days (HR=0.673) compared to mood stabilizers alone 3

Mandatory Treatment Requirements for Bipolar II Depression

If using Spravato in bipolar II depression, you MUST:

1. Concurrent mood stabilizer therapy is non-negotiable - All studies showing safety used lithium or valproate alongside esketamine 3, 4, 5

2. Blood pressure monitoring is essential - Patients with bipolar disorder may have comorbid hypertension; systolic BP >160 mmHg with symptoms requires intervention (e.g., nifedipine) 6

3. Weekly mood monitoring during acute phase - Screen specifically for irritability, decreased need for sleep, increased energy, and grandiosity 5

4. Consider limiting to acute treatment initially - The safety data is strongest for the 4-week acute phase; maintenance requires more cautious monitoring 5

Clinical Algorithm for Bipolar II Depression

Step 1: Confirm patient does NOT have:

• Recent hypomania/mania (within past 2-4 weeks)
• Rapid cycling pattern
• Mixed features
• Cardiovascular contraindications per FDA label 1

Step 2: Ensure adequate mood stabilizer coverage:

• Lithium or valproate at therapeutic levels for at least 2-4 weeks prior 7
• For BD II, this is clinician discretion but strongly recommended based on research evidence

Step 3: Initiate esketamine with standard TRD dosing:

• 56 mg or 84 mg twice weekly for 4 weeks 1
• Monitor BP before, at 40 minutes post-dose, and throughout 2-hour observation
• Screen for dissociation, sedation, and emerging hypomanic symptoms

Step 4: Reassess at 4 weeks:

• If response achieved and no mood instability: consider maintenance
• If manic symptoms emerge: discontinue immediately 1
• If inadequate response: adjust dose or consider alternative

Common Pitfalls to Avoid

1. Do not use without mood stabilizer - This is the single most important safety measure based on all available evidence

2. Do not assume bipolar I and II have identical risk profiles - The 2025 study showed females with bipolar disorder had significantly lower manic switch risk at longer intervals, suggesting potential sex-based differences 3

3. Do not reduce monitoring frequency prematurely - The Yale data shows manic switches occurred during maintenance, not acute treatment 5

4. Do not ignore cardiovascular monitoring - Bipolar patients may have higher baseline cardiovascular risk; one case required antihypertensive intervention 6

The evidence suggests Spravato can be used safely and effectively in bipolar II depression when proper precautions are taken, particularly concurrent mood stabilizer therapy and vigilant monitoring for mood destabilization.